Scholars Central

Conference abstractPublished 3 Aug 2015

Does copper transporter 2 (CTR2) quaternary structures and subcellular localisation determine sensitivity of breast cancer cell lines to platinum-based chemotherapies?

Authors: Stephen Assinder, Janine Street, Stuart Fraser

The University of Sydney, Australia

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Influx of reduced copper into cells is mediated by the copper transporters CTR1 and CTR2. CTR1 and 2 are also thought to be responsible for the influx of platinum-based cytotoxic drugs used in the treatment of cancers. Evidence suggests that the sensitivity of a cell to such drugs (eg. cisplatin) might relate to the amount of CTR2 present. Immunohistochemical analysis of breast cancer tissue microarrays demonstrated an increased amount of CTR2 relative to CTR1 in both invasive ductal and invasive epithelial carcinomas as compared to normal breast tissue.We than tested the hypothesis thatgreater amounts of CTR2 reduced sensitivity of breast cancer cells tocisplatin. Levels of CTR2 proteins were assayed in a normal breast epithelial cell line (184B5), and 3 representative breast cancer cell lines (MCF7, HCC1806, MDA-MB-468) by western blot. Western blot analysis detected monomeric and dimericCTR2. In the relatively cisplatin insensitive MCF7 cell line (IC50 > 20 Ã?¼mol.L-1) there is predominantly dimeric form. Cisplatin sensitive HCC1806 and 184B5 (IC50=5 Ã?¼mol.L-1), have predominantly monomeric CTR2. The highly cisplatin sensitive (IC50=0.5 Ã?¼mol.L-1) MDA-MB-468 breast cancer cells have significantly less total CTR2 protein, butsimilar amounts of CTR2 monomer and dimer. Confocal imaging demonstrated that cisplatin resistant MCF7 cells exhibit peri-nuclear CTR2 while more sensitive cell linesshow an unexpected CTR2 nuclear localisation. We conclude that the amount of total CTR2, its quarternary structure and sub-cellular localisation may determine cisplatin sensitivity. Dimerisation of CTR2 might prevent localisation to the nucleus in turn preventing cisplatin from trafficking to the nucleus and resultant DNA damage and apoptosis.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Cancer Science & Therapy.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalCancer Science & Therapy
  • SubjectOncology & Cancer
  • BylineArticles whose byline prints “Stephen Assinder”
  • BylineArticles whose byline prints “Janine Street”
  • BylineArticles whose byline prints “Stuart Fraser”